| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02865369 | Chronic Hepatitis C | Drug: Daclatasvir and Asunaprevir | Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital | | 2016-09-01 | 2017-03-04 |
| NCT01830205 | Hepatitis C | Drug: Daclatasvir | Bristol-Myers Squibb | Phase 1 | 2012-09-01 | 2015-11-13 |
| NCT02032901 | Hepatitis C | Drug: Daclatasvir|Drug: Sofosbuvir | Bristol-Myers Squibb | Phase 3 | 2014-01-01 | 2015-09-29 |
| NCT03004625 | Hepatitis C | Drug: daclatasvir|Drug: asunaprevir|Drug: Ribavirin | Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital | Phase 3 | 2016-11-01 | 2017-02-28 |
| NCT02159352 | Hepatitis C | Drug: Daclatasvir|Drug: Darunavir|Drug: Ritonavir|Drug: Lopinavir/Ritonavir | Bristol-Myers Squibb | Phase 1 | 2014-06-01 | 2015-10-29 |
| NCT02268864 | Hepatitis C, Chronic | Drug: Simeprevir|Drug: Daclatasvir | Janssen-Cilag International NV | Phase 2 | 2015-01-01 | 2017-02-07 |
| NCT02624063 | Hepatitis C, Chronic | Drug: Daclatasvir + Sofosbuvir|Drug: Simeprevir + Sofosbuvir | Federal University of So Paulo | Phase 4 | 2015-12-01 | 2017-02-17 |
| NCT02756936 | Healthy | Drug: Daclatasvir Zeta|Drug: Clatazev | Genuine Research Center, Egypt|Zeta Pharma Pharmaceutical Industries | Phase 1 | 2016-02-01 | 2017-02-27 |
| NCT02032888 | Hepatitis C | Drug: Daclatasvir|Drug: Sofosbuvir | Bristol-Myers Squibb | Phase 3 | 2014-02-01 | 2015-09-24 |
| NCT02551861 | Hepatitis C | Drug: Daclatasvir|Drug: Sofosbuvir|Drug: Ribavirin | Bristol-Myers Squibb | Phase 2 | 2015-12-01 | 2016-01-14 |
| NCT02565862 | Hepatitis C|Diabetes Mellitus|Insulin Resistance | Drug: Daclatasvir|Drug: Metformin | Radboud University | Phase 1 | 2016-01-01 | 2016-04-06 |
| NCT02675127 | Healthy | Drug: Daktavira|Drug: Daklinza | Genuine Research Center, Egypt|European Egyptian Pharmaceutical Industries | Phase 1 | 2015-12-01 | 2016-02-03 |
| NCT01492504 | Hepatitis C | Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) | Bristol-Myers Squibb | | 2012-02-01 | 2017-03-03 |
| NCT03063879 | Hepatitis C, Chronic|Chronic Renal Failure | Drug: Sofosbuvir 400 mg and daclatasvir 60 mg | Tehran University of Medical Sciences|Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|Isfahan University of Medical Sciences|Tabriz University of Medical Sciences | Phase 4 | 2017-03-01 | 2017-02-23 |
| NCT02262728 | Hepatitis C, Chronic | Drug: Simeprevir|Drug: Daclatasvir|Drug: Sofosbuvir | Janssen Research & Development, LLC | Phase 2 | 2014-09-01 | 2016-12-19 |
| NCT02309450 | Hepatitis C Virus Genotype 4 Infection | Drug: .Asunaprevir, Daclatasvir and BMS - 791325 | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Phase 2 | 2014-12-01 | 2016-02-01 |
| NCT02640157 | Chronic Hepatitis C|Hepatitis C Virus|Genotype 3 Hepatitis C Virus | Drug: ABT-493/ABT-530|Drug: sofosbuvir|Drug: daclatasvir|Drug: daclatasvir | AbbVie | Phase 3 | 2015-12-01 | 2017-02-08 |
| NCT02556086 | Hepatitis C | Drug: Daclatasvir|Drug: Sofosbuvir | Bristol-Myers Squibb | Phase 2 | 2015-12-01 | 2016-01-19 |
| NCT02580474 | Hepatitis C | Drug: Daclatasvir plus Asunaprevir | Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent's Hospital, Korea|Konkuk University Hospital|Cheongju St. Mary's Hospital, Cheongju, Korea|Severance Hospital|Korea University Guro Hospital|Eulji General Hospital|The Catholic University of Korea | Phase 4 | 2016-02-01 | 2016-02-24 |
| NCT02496078 | Hepatitis C | Drug: Daclatasvir|Drug: Asunaprevir | Bristol-Myers Squibb | Phase 3 | 2015-08-01 | 2017-03-03 |
